SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

US FDA restricts sale of cholesterol-lowering drug Simvastatin

13 Jun 2011 Evaluate

The US Food and Drug Administration (USFDA), health regulator of the US market, has issued a warning that the 80 mg version of cholesterol-lowering drug Simvastatin should not be prescribed to new patients as the high-dose version has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use.

Indian pharmaceutical firms like Ranbaxy, Dr Reddy’s Labs, Lupin and Zydus Cadila are selling simvastatin in the United States. Simvastatin is used to lower the amount of low-density lipoprotein (LDL) to reduce the risk of heart attacks and strokes. There would be no major impact on generic players, as the margin remains less due to the presence of too many copycat versions. The patented version of Simvastatin-Zocor, manufactured by Merck, was approved in 1991 and went off patent in 2006. Since its patent expiry, all major generic players including Ranbaxy, Dr Reddy’s, Zydus Cadila and Lupin, launched copycat versions in the US market. Zydus Pharmaceuticals (USA) Inc, launched generic simvastatin in 2006. Lupin and Dr Reddy’s Labs received approval to sell simvastatin in the US in 2007.
According to the FDA, about 2.1 million patients were prescribed for simvastatin 80 mg last year. Simvastatin is the second most prescribed drug in the US with 94 million prescriptions dispensed in 2010, according to IMS Health.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×